Wedge Capital Management’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Wedge Capital Management’s Portfolio RVLP Stock Details RVLP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-342,093	Closed	-$1.11M	–	527
2021 Q1	$1.11M	Buy	342,093 +393	+0.1%	+$1.62K	0.01%	306
2020 Q4	$1.41M	Buy	341,700 +221,669	+185%	+$1.28M	0.02%	308
2020 Q3	$649K	Hold	120,031	–	–	0.01%	346
2020 Q2	$808K	Sell	120,031 -183,563	-60%	-$898K	0.01%	311
2020 Q1	$965K	Buy	303,594 +100,219	+49%	+$534K	0.02%	296
2019 Q4	$1.42M	Buy	203,375 +95,952	+89%	+$512K	0.02%	305
2019 Q3	$413K	Buy	+107,423	New	+$364K	﹤0.01%	430

Other funds holding RVLP

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Rovida Advisors Fort Lauderdale, Florida $116M AUM 12.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wedge Capital Management's RVLP Position: Q2 2021 in Review

Wedge Capital Management sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q2 2021, closing a stake of 342,093 shares — an estimated $1.11M sold.

Wedge Capital Management first reported a position in RVLP in Q3 2019 and held it in 7 quarters. The position peaked at $1.42M in Q4 2019. 46 funds tracked by Wall St. Rank hold RVLP as of Q2 2021.

Wedge Capital Management reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q2 2021 after selling out during the quarter.
Wedge Capital Management sold 342,093 RVL Pharmaceuticals plc Ordinary Shares shares in Q2 2021, an estimated $1.11M.
Wedge Capital Management first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q3 2019 and held it in 7 quarters.
Wedge Capital Management's RVL Pharmaceuticals plc Ordinary Shares position peaked at $1.42M in Q4 2019.
46 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q2 2021.

Based on Wedge Capital Management's 13F filing for Q2 2021, filed 14 Jul 2021.